IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GLUCAGON-LIKE : CIVIL ACTION

PEPTIDE-1 RECEPTOR AGONISTS

(GLP-1 RAS) PRODUCTS

LIABILITY LITIGATION

: MDL No. 3094 : 24-md-3094

THIS DOCUMENT RELATES TO:

HON. KAREN SPENCER MARSTON

ALL ACTIONS/ALL CASES :

ORDER

AND NOW, this 15th day of August, 2025, upon consideration of Defendant Novo
Nordisk's Motion to Exclude the Opinion and Testimony of Drs. Daniel Raines and Eliot Siegel
(Doc. No. 360), Defendant Eli Lilly and Company's Motion to Exclude Opinions that
Gastroparesis Can Reliably Be Diagnosed Without Contemporaneous Objective Testing (Doc.
No. 361), Plaintiffs' opposition brief (Doc. No. 379), Defendants' joint reply brief (Doc. No.
385), Plaintiffs' Motion to Exclude Opinions of Linda A. Nguyen, MD Under Rule 702 (Doc.
No. 359), Defendants' joint opposition brief (Doc. No. 377), Plaintiffs' reply brief (Doc.
No. 386), the testimony taken during an evidentiary hearing on May 14, 2025, the argument of counsel at a hearing on May 19, 2025, Plaintiffs' Motion for Leave to File Supplement to the Record on Cross Cutting Issue No. 1 (Doc. No. 447), Defendants' briefs in opposition (Doc.
Nos. 451–52), Plaintiffs' reply brief (Doc. No. 453), and the arguments made by counsel at a status hearing on July 29, 2025, it is **ORDERED** as follows:

- 1. Plaintiffs' Motion for Leave to File Supplement to the Record on Cross Cutting Issue No. 1 (Doc. No. 447) is **GRANTED.**
- 2. Defendants' motions to exclude the opinions of Drs. Raines and Siegel made in connection with Cross Cutting Issue No. 1 (Doc. Nos. 360–61) are **GRANTED.**

3. Plaintiffs' motion to exclude the opinion of Dr. Nguyen (Doc. No. 359) is

DENIED.

4. Any Plaintiff claiming to suffer (or have suffered) from gastroparesis, must show that their diagnosis is based on a properly performed gastric emptying study (scintigraphy, breath test, or WMC).

IT IS SO ORDERED.

/s/ Karen Spencer Marston
KAREN SPENCER MARSTON, J.